Reuters logo
3 个月内
BRIEF-Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial
2017年5月4日 / 下午1点16分 / 3 个月内

BRIEF-Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial

1 分钟阅读

May 4 (Reuters) - Oncomed Pharmaceuticals Inc:

* Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial

* Oncomed Pharmaceuticals Inc - trial will be conducted at five centers in U.S. And is expected to enroll approximately 30 patients. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below